BackgroundVascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Six forms of human VEGF mRNA encoding VEGF proteins of 121, 145, 165, 183, 189, and 206 amino acids are produced from a single gene as a result of alternative splicing. VEGF165 appears to be the major gene product found in human tissue and is the most effective angiogenic factor in the VEGF family.
ImmunogenRecombinant human VEGF165, 27~191 aa of VEGF
PurificationPurified by protein A column
Storage/StabilityStore at -20 oC upon arrival for one year. Avoid repeated freeze-thaw cycles.
Form Or Antibody
Form of AntibodyEach vial at least contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of 0.01 M PBS, PH7.4, 1 mg/ml BSA, 20 % glycerol, 0.01 % (w/v) NaN3
Product Information
LimitationFor research use only and are not intended for diagnostic or therapeutic use.
Isotope:
Rabbit IgG
Recommended DilutionsWB: 1:1000-5000